期刊文献+

Relationship of PARG with PARP,VEGF and b-FGF in Colorectal Carcinoma 被引量:7

Relationship of PARG with PARP,VEGF and b-FGF in Colorectal Carcinoma
暂未订购
导出
摘要 Objective: To investigate the relationship of poly(ADP-ribose)glycohydrolase(PARG) with poly (ADP-ribose) polymerase(PARP), vascular endothelial growth factor (VEGF) and basic fibroblast growth factor(b-FGF) in colorectal carcinoma(CRC). Methods: Immunohistochemical analysis was used to detect PARG, PARP, VEGF and b-FGF in human colorectal carcinoma. Flow cytometry was used to detect PARG and PARP in murine CT26 cell line. Gallotannin (GLTN) was served as PARG inhibitor. Results: The individual positive rates of PARG, PARE VEGF and b-FGF were 55.81%(24/43), 97.67%(42/43), 79.07%(34/43) and 81.40%(35/43), respectively, which were significantly higher than those of control group. The positive PARG was correlated to PARP(r=0.3703, P〈0.05) and b-FGF (r=0.4838, P〈0.05). The positive PARP was correlated to VEGF (r=0.3968, P〈0.05) and b-FGF (r=0.5610, P〈0.05). Both PARG and PARP were expressed in CT26 cells. The positive staining rates of PARG and PARP in GLTN-treated group were 7.3% and 52.38%, respectively. They were markedly reduced than those of control group (55.41% and 95.28%, P〈0.01, n=10000). Conclusion: The data suggest that PARG expression probably plays a role for VEGF and b-FGF expression in colorectal carcinoma. Objective: To investigate the relationship of poly(ADP-ribose)glycohydrolase(PARG) with poly (ADP-ribose) polymerase(PARP), vascular endothelial growth factor (VEGF) and basic fibroblast growth factor(b-FGF) in colorectal carcinoma(CRC). Methods: Immunohistochemical analysis was used to detect PARG, PARP, VEGF and b-FGF in human colorectal carcinoma. Flow cytometry was used to detect PARG and PARP in murine CT26 cell line. Gallotannin (GLTN) was served as PARG inhibitor. Results: The individual positive rates of PARG, PARE VEGF and b-FGF were 55.81%(24/43), 97.67%(42/43), 79.07%(34/43) and 81.40%(35/43), respectively, which were significantly higher than those of control group. The positive PARG was correlated to PARP(r=0.3703, P〈0.05) and b-FGF (r=0.4838, P〈0.05). The positive PARP was correlated to VEGF (r=0.3968, P〈0.05) and b-FGF (r=0.5610, P〈0.05). Both PARG and PARP were expressed in CT26 cells. The positive staining rates of PARG and PARP in GLTN-treated group were 7.3% and 52.38%, respectively. They were markedly reduced than those of control group (55.41% and 95.28%, P〈0.01, n=10000). Conclusion: The data suggest that PARG expression probably plays a role for VEGF and b-FGF expression in colorectal carcinoma.
出处 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2009年第2期135-141,共7页 中国癌症研究(英文版)
基金 supported by the National Natural Science Foundation of China (No 30870946) Natural Science Foundation of CQ CSTC(CSTC, 2006BB5288)
关键词 PARG PARP VEGF B-FGF Colorectal carcinoma PARG PARP VEGF b-FGF Colorectal carcinoma
  • 相关文献

参考文献3

二级参考文献111

  • 1李治国,王继见.核转录因子在大肠癌中的研究进展[J].现代医药卫生,2005,21(19):2621-2622. 被引量:2
  • 2高静,王娅兰.大肠癌核基质蛋白变化与其生物学行为的关系[J].重庆医科大学学报,2006,31(3):302-306. 被引量:3
  • 3郝兰香,王娅兰,李圆圆.大肠癌PARP表达与P-selectin和ICAM-1表达的相关性[J].基础医学与临床,2006,26(8):882-887. 被引量:17
  • 4[1]Cancer facts and figures 2006.Atlanta:American Cancer Society,2006.Available URL from:http://www.cancer.org/ downloads/STT/CAFF2006PWSecured.pdf
  • 5[2]Obrand DI,Gordon PH.Incidence and patterns of recurrence following curative resection for colorectal carcinoma.Dis Colon Rectum 1997; 40:15-24
  • 6[3]Petrelli N,Douglass HO Jr,Herrera L,Russell D,Stablein DM,Bruckner HW,Mayer RJ,Schinella R,Green MD,Muggia FM.The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma:a prospective randomized phase Ⅲ trial.Gastrointestinal Tumor Study Group.J Clin Oncol 1989; 7:1419-1426
  • 7[4]Poon MA,O'Connell MJ,Moertel CG,Wieand HS,Cullinan SA,Everson LK,Krook JE,Mailliard JA,Laurie JA,Tschetter LK.Biochemical modulation of fluorouracil:evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma.J Clin Oncol 1989;7:1407-1418
  • 8[5]Piedbois P,Buyse M,Rustum Y,Machover D,Erlichman C,Carlson R,Valone F,Labianca R,Doroshow J,Petrelli N.Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer:evidence in terms of response rate.
  • 9[6]Advanced Colorectal Cancer Meta-Analysis Project.J Clin Oncol 1992; 10:896-903de Gramont A,Figer A,Seymour M,Homerin M,Hmissi A,Cassidy J,Boni C,Cortes-Funes H,Cervantes A,Freyer G,Papamichael D,Le Bail N,Louvet C,Hendler D,de Braud F,Wilson C,Morvan F,Bonetti A.Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.J Clin Oncol 2000; 18:2938-2947
  • 10[7]Douillard JY,Cunningham D,Roth AD,Navarro M,James RD,Karasek P,Jandik P,Iveson T,Carmichael J,Alakl M,Gruia G,Awad L,Rougier P.Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer:a multicentre randomised trial.Lancet 2000; 355:1041-1047

共引文献16

同被引文献22

引证文献7

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部